Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

Lauseker M, Sacha T, Klamova H, Yakoleva J, Lomaia E, Milojkovic D, Fabisch C, Nicolini FE, Olsson-Stromberg U, Zackova D, Lewandowski K, Ernst P, Castagnetti F, Hirschbühl K, Zupan I, Voskanyan A, Gołos A, Frietsch JJ, Gil J, Faber E, Krause S, Parry A, Saussele S, Heibl S, Franke GN, Casado LF, Paczkowska E, Hebart H, Eder M, Anhut P, Trautmann-Grill K, Szczepanek E, Südhoff T, Patkowska E, Kiani A, Ernst T, Apperley J, Mayer J, Hochhaus A, Pfirrmann M, Brioli A (2026)

Publication Type: Journal article

Publication year: 2026

Journal

DOI: 10.1038/s41375-026-02875-9

Abstract

Currently there is no established prognostic scoring system for patients with chronic myeloid leukemia (CML) in blast phase (BP). This study aimed to identify prognostic factors of CML-BP in a large cohort of prospectively and retrospectively collected patients and to develop a readily available prognostic scoring system at the onset of BP to enable future comparison between different trials and series. The analyses were based on 275 patients from thirteen countries, collected within the European LeukemiaNet Blast Phase Registry with a median observation time of 45 months and a median OS of 18.9 months. A Cox proportional hazards model for overall survival (OS) was employed, missing values were imputed. The study identified six independent prognostic factors: blast percentage, platelet count, age (all at onset of CML-BP), immunophenotype of BP, extramedullary disease, and previous history of CML. The low-risk group, encompassing 14% of patients, had a median OS of 97 months, the intermediate-risk group (59% of patients) of 22 months, and the high-risk group (27% of patients) of 9 months. Cross-validation demonstrated a good performance of the score, although external validation is strongly recommended. Despite the inherent limitations of registry data, the findings offer robust insights into prognostic factors for CML-BP.

Authors with CRIS profile

Involved external institutions

Uppsala University Hospital / Akademiska sjukhuset Sweden (SE) Hammersmith Hospital United Kingdom (GB) Ospedaliero Universitaria di Bologna Policlinico S.Orsola-Malpighi Italy (IT) Ludwig-Maximilians-Universität (LMU) Germany (DE) First Pavlov State Medical University of St. Petersburg Russian Federation (RU) Jagiellonian University / Uniwersytet Jagielloński (UJ) Poland (PL) Poznan University of Medical Sciences / Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Poland (PL) Universitätsklinikum Jena Germany (DE) Federal Almazov Medical Research Centre Russian Federation (RU) Centre Léon-Bérard (UNICANCER) France (FR) University Hospital Brno Czech Republic (CZ) University Hospital Olomouc / Fakultní Nemocnice Olomouc Czech Republic (CZ) Instytut Centrum Zdrowia Matki Polki w Łodzi (ICZMP) / Polish Mother’s Memorial Hospital Research Institute Poland (PL) Centre Hospitalier Annecy Genevois France (FR) Institute of Hematology and Blood Transfusion / Instytut Hematologii i Transfuzjologi (IHiT) Poland (PL) Universität Leipzig Germany (DE) Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza Poland (PL) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Universitätsklinikum Mannheim / University Medical Centre Mannheim (Universitätsmedizin Mannheim) Germany (DE) Klinikum Wels-Grieskirchen Austria (AT) Universitätsklinikum Würzburg Germany (DE) Klinikum Passau Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Imperial College Healthcare NHS Trust United Kingdom (GB) Ljubljana University Medical Centre (Ljubljana UMC) / Univerzitetni klinični center Ljubljana Slovenia (SI) Stauferklinikum Schwäbisch Gmünd Germany (DE) Universität Augsburg Germany (DE) Institute of Hematology after Prof. R.H. Yeolyan / ՊՐՈՖԵՍՈՐ Ռ.Հ. ՅՈԼՅԱՆԻ ԱՆՎԱՆ ԱՐՅՈՒՆԱԲԱՆԱԿԱՆ ԿԵՆՏՐՈՆ Armenia (AM) Onkologische Schwerpunktpraxis Bielefeld Germany (DE) University Hospital of Toledo / Hospital Universitario de Toledo Spain (ES) Pomeranian Medical University / Pomorski Uniwersytet Medyczny w Szczecinie (PMU) Poland (PL)

How to cite

APA:

Lauseker, M., Sacha, T., Klamova, H., Yakoleva, J., Lomaia, E., Milojkovic, D.,... Brioli, A. (2026). Development of a prognostic scoring system for chronic myeloid leukemia in blast phase. Leukemia. https://doi.org/10.1038/s41375-026-02875-9

MLA:

Lauseker, Michael, et al. "Development of a prognostic scoring system for chronic myeloid leukemia in blast phase." Leukemia (2026).

BibTeX: Download